168 related articles for article (PubMed ID: 34906030)
1. Epidemiology, healthcare resource utilization and healthcare costs for spinal muscular atrophy in Alberta, Canada.
Chen G; Sharif B; Gerber B; Farris MS; Cowling T; Cabalteja C; Wu JW; Maturi B; Klein-Panneton K; Jean K Mah
J Med Econ; 2021 Nov; 24(sup1):51-59. PubMed ID: 34906030
[TBL] [Abstract][Full Text] [Related]
2. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.
Droege M; Sproule D; Arjunji R; Gauthier-Loiselle M; Cloutier M; Dabbous O
J Med Econ; 2020 Jan; 23(1):70-79. PubMed ID: 31322019
[No Abstract] [Full Text] [Related]
3. Health resource utilization and cost before versus after initiation of second-generation long-acting injectable antipsychotics among adults with schizophrenia in Alberta, Canada: a retrospective, observational single-arm study.
Wong KO; Klarenbach SW; Martins KJB; Chue P; Dursun SM; Snaterse M; Guigue A; So H; Luu H; Vu K; Richer L
BMC Psychiatry; 2022 Jul; 22(1):444. PubMed ID: 35780116
[TBL] [Abstract][Full Text] [Related]
4. The economic burden of spinal muscular atrophy.
Armstrong EP; Malone DC; Yeh WS; Dahl GJ; Lee RL; Sicignano N
J Med Econ; 2016 Aug; 19(8):822-6. PubMed ID: 27264163
[TBL] [Abstract][Full Text] [Related]
5. Significant healthcare burden and life cost of spinal muscular atrophy: real-world data.
Chan SHS; Wong CKH; Wu T; Wong W; Yu MKL; Au ICH; Chan GCF
Eur J Health Econ; 2023 Nov; 24(8):1373-1382. PubMed ID: 36403177
[TBL] [Abstract][Full Text] [Related]
6. Systematic Literature Review to Assess the Cost and Resource Use Associated with Spinal Muscular Atrophy Management.
Paracha N; Hudson P; Mitchell S; Sutherland CS
Pharmacoeconomics; 2022 Apr; 40(Suppl 1):11-38. PubMed ID: 34761360
[TBL] [Abstract][Full Text] [Related]
7. Costs of health services utilization of people with fetal alcohol spectrum disorder by sex and age group in Alberta, Canada.
Thanh NX; Jonsson E
J Popul Ther Clin Pharmacol; 2014; 21(3):e421-30. PubMed ID: 25658807
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Adult Patients With SMA Treated in US Hospital Settings: A Natural History Study in the Premier Healthcare Database.
Johnson NB; Proud C; Wassel CL; Dreyfus J; Cochrane T; Paradis AD
J Neuromuscul Dis; 2021; 8(4):569-578. PubMed ID: 33843692
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and patient journey of Rett syndrome in the United States: a real-world evidence study.
May D; Kponee-Shovein K; Mahendran M; Downes N; Sheng K; Lefebvre P; Cheng WY
BMC Neurol; 2023 Apr; 23(1):141. PubMed ID: 37016355
[TBL] [Abstract][Full Text] [Related]
10. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
[TBL] [Abstract][Full Text] [Related]
11. The Economic Impact and Health-Related Quality of Life of Spinal Muscular Atrophy. An Analysis across Europe.
Peña-Longobardo LM; Aranda-Reneo I; Oliva-Moreno J; Litzkendorf S; Durand-Zaleski I; Tizzano E; López-Bastida J
Int J Environ Res Public Health; 2020 Aug; 17(16):. PubMed ID: 32764338
[No Abstract] [Full Text] [Related]
12. Direct Medical Costs of Spinal Muscular Atrophy in the Catalonia Region: A Population-Based Analysis.
Darbà J
Clin Drug Investig; 2020 Apr; 40(4):335-341. PubMed ID: 32144652
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology and economic burden of Huntington's disease: a Canadian provincial public health system perspective.
Shaw E; Mayer M; Ekwaru P; McMullen S; Graves E; Wu JW; Budd N; Maturi B; Cowling T; Mestre TA
J Med Econ; 2022; 25(1):212-219. PubMed ID: 35073826
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
[TBL] [Abstract][Full Text] [Related]
15. Social/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain.
López-Bastida J; Peña-Longobardo LM; Aranda-Reneo I; Tizzano E; Sefton M; Oliva-Moreno J
Orphanet J Rare Dis; 2017 Aug; 12(1):141. PubMed ID: 28821278
[TBL] [Abstract][Full Text] [Related]
16. Spinal muscular atrophy: epidemiology and health burden in children - a Polish national healthcare database perspective before introduction of SMA-specific treatment.
Kostera-Pruszczyk A; Napiórkowski Ł; Szymańska K; Jędrzejczak J; Roszkowski M; Słowiński J; Frączek A; Ryglewicz D; Więckowska B
Neurol Neurochir Pol; 2021; 55(5):479-484. PubMed ID: 34664710
[TBL] [Abstract][Full Text] [Related]
17. Healthcare resource utilisation and direct medical cost for individuals with 5q spinal muscular atrophy in Sweden.
Sejersen T; Graham S; Ekström AB; Kroksmark AK; Kwiatkowska M; Ganz ML; Justo N; Gertow K; Simpson A
Eur J Health Econ; 2024 Apr; ():. PubMed ID: 38642267
[TBL] [Abstract][Full Text] [Related]
18. Healthcare utilization and costs for spinal conditions in Ontario, Canada - opportunities for funding high-value care: a retrospective cohort study.
Rampersaud YR; Power JD; Perruccio AV; Paterson JM; Veillette C; Coyte PC; Badley EM; Mahomed NN
Spine J; 2020 Jun; 20(6):874-881. PubMed ID: 32007652
[TBL] [Abstract][Full Text] [Related]
19. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments.
Dangouloff T; Botty C; Beaudart C; Servais L; Hiligsmann M
Orphanet J Rare Dis; 2021 Jan; 16(1):47. PubMed ID: 33485382
[TBL] [Abstract][Full Text] [Related]
20. Economic burden of chronic pain in Alberta, Canada.
Thanh NX; Tanguay RL; Manhas KJP; Kania-Richmond A; Kashuba S; Geyer T; Pereira JX; Wasylak T
PLoS One; 2022; 17(8):e0272638. PubMed ID: 35960750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
